Pharmacyte Biotech Inc. (PMCB)
NASDAQ (CM) NASDAQ (CM) Primary Summary
PMCB Chart
Pharmacyte Biotech Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 3 | $2 | $2.16 | $0.16 | 8% |
| CAL CoreCap Advisors LLC CoreCap Advisors LLC | 4 | $2.92 | $2.88 | -$0.04 | -1.37% |
 Lukas Lindgren Abound Wealth Management | 1 | $0.67 | $0.7 | $0.03 | 4.48% |
| DP Drew Phillips Fortitude Family Office LLC | 1 | $0.67 | $0.71 | $0.04 | 5.97% |
 Matthew Stead Sachetta, LLC | 14 | $31 | $9.65 | -$21.35 | -68.87% |
Pharmacyte Biotech Inc. (PMCB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Pharmacyte Biotech Inc. ever had a stock split?
Pharmacyte Biotech Inc. Profile
| Biotechnology Industry | Healthcare Sector | Joshua N. Silverman CEO | NASDAQ (CM) Exchange | 71715X203 CUSIP |
| US Country | 2 Employees | - Last Dividend | 12 Jul 2021 Last Split | 17 Sep 2010 IPO Date |
Overview
PharmaCyte Biotech, Inc. is a pioneering biotechnology company based in Las Vegas, Nevada, committed to the development and commercialization of novel cellular therapies. These therapies target a range of serious conditions including cancer, diabetes, and malignant ascites, primarily within the United States. Utilizing its proprietary Cell-in-a-Box technology—a unique cellulose-based live cell encapsulation platform—PharmaCyte aims to revolutionize treatment options for patients suffering from various types of cancer like advanced pancreatic cancer, as well as both Type 1 and insulin-dependent Type 2 diabetes. Initially known as Nuvilex, Inc., the company underwent a rebranding to PharmaCyte Biotech, Inc. in January 2015, marking a pivotal shift in its strategic focus towards leveraging cellular therapies. Since its inception in 1996, PharmaCyte has been at the forefront of integrating innovative biotechnology approaches to address critical medical needs.
Products and Services
- Cancer Therapies:
- Diabetes Therapy:
- Therapies Based on Cannabis Constituents:
- Research Partnership for Melligen Cells:
PharmaCyte’s cancer therapy development centers around the Cell-in-a-Box technology. This approach focuses on treating various types of cancer, especially advanced and inoperable pancreatic cancer, by encapsulating live cells that are capable of converting inactive chemotherapy drugs into their active form directly at the cancer site. This methodology aims to minimize the adverse effects typically associated with systemic chemotherapy treatments, thus potentially offering a more targeted and effective cancer therapy option.
The company is also venturing into the realm of diabetes treatment, with a particular focus on Type 1 diabetes and insulin-dependent Type 2 diabetes. PharmaCyte is developing a therapy that involves encapsulating genetically modified insulin-producing cells. By doing so, the company hopes to create a bioartificial pancreas that can regulate insulin levels in the body more effectively than current treatments, thereby offering a groundbreaking solution for diabetes management.
In addition to conventional cellular therapies, PharmaCyte is exploring treatments derived from the cannabis plant for cancer. This innovative approach seeks to harness the medicinal properties of cannabis constituents in order to develop alternative cancer therapies that could offer relief and potentially more effective treatment options for patients undergoing cancer treatment.
PharmaCyte holds a research agreement with the University of Technology, Sydney, aimed at advancing a version of melligen cells capable of treating diabetes. This collaboration underscores the company’s commitment to leveraging global research expertise and cutting-edge biotechnology in its quest to develop effective treatments for diabetes.
